Open AccessChimeric Antigen Receptor T‐Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside
Author(s) -
RodriguezCartagena Luis G.,
Bowles Bradley S.,
Kurani Shaheen S.,
Windebank Anthony J.,
Kenderian Saad S.,
GreenbergWorisek Alexandra J.
Publication year - 2018
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12586
Subject(s) - chimeric antigen receptor , medicine , immunotherapy , cancer , transplantation , radiation therapy , genetic enhancement , cancer immunotherapy , leukemia , suicide gene , cell therapy , disease , cancer research , immunology , oncology , cell , biology , gene , genetics , biochemistry
More than 2 decades after the initial concept of chimeric antigen receptor T (CART) cell was described, incremental improvements in molecular biology, virology, Tcell immunology, and manufacturing process led to regulatory approval of the first CART cell product for the treatment of Bcell malignancies. Here, we detail the unique translational pathway of CART cell therapy, highlighting challenges and facilitators of its translation that may be applicable to future cell and gene therapies in development.